

1 **Trans-ancestry genome-wide analysis of atrial fibrillation provides new**
2 **insights into disease biology and enables polygenic prediction of**
3 **cardioembolic risk**

4
5 Kazuo Miyazawa¹, Kaoru Ito^{1*}, Zhaonan Zou², Hiroshi Matsunaga^{1,3}, Satoshi Koyama^{1,4,5}, Hirotaka
6 Ieki^{1,3}, Seitaro Nomura³, Masato Akiyama^{6,7}, Ryo Kurosawa¹, Hiroki Yoshida^{1,3}, Kouichi Ozaki^{1,8},
7 Yoshihiro Onouchi^{1,9}, BioBank Japan Project¹⁰, Atsushi Takahashi^{6,11}, Koichi Matsuda¹², Yoshinori
8 Murakami¹³, Hiroyuki Aburatani¹⁴, Michiaki Kubo¹⁵, Yukihide Momozawa¹⁶, Chikashi Terao⁶,
9 Shinya Oki², Hiroshi Akazawa³, Yoichiro Kamatani^{6,12}, and Issei Komuro^{3*}

10

11 ¹Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative Medical
12 Sciences, Yokohama, Japan ²Department of Drug Discovery Medicine, Kyoto University Graduate
13 School of Medicine, Kyoto, Japan ³Department of Cardiovascular Medicine, Graduate School of
14 Medicine, The University of Tokyo, Tokyo, Japan ⁴Program in Medical and Population Genetics,
15 Broad Institute of Harvard and MIT, Cambridge, MA, USA ⁵Cardiovascular Research Center,
16 Massachusetts General Hospital, Boston, MA, USA ⁶Laboratory for Statistical and Translational
17 Genetics, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan ⁷Department of Ocular
18 Pathology and Imaging Science, Kyushu University Graduate School of Medical Sciences, Fukuoka,
19 Japan ⁸Division for Genomic Medicine, Medical Genome Center, National Center for Geriatrics and
20 Gerontology, Obu, Japan ⁹Department of Public Health, Chiba University Graduate School of
21 Medicine, Chiba, Japan ¹⁰Institute of Medical Science, The University of Tokyo, Tokyo, Japan
22 ¹¹Department of Genomic Medicine, Research Institute, National Cerebral and Cardiovascular
23 Center, Suita, Japan ¹²Department of Computational Biology and Medical Science, Graduate School
24 of Frontier Sciences, The University of Tokyo, Tokyo, Japan ¹³Division of Molecular Pathology,
25 Institute of Medical Science, The University of Tokyo, Tokyo, Japan ¹⁴Genome Science Division,
26 Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 ¹⁵RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan ¹⁶Laboratory for Genotyping
28 Development, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan
29
30 Correspondence should be addressed to K.I. (kaoru.ito@riken.jp), Y.K. (kamatani.yoichiro@edu.k.u-
31 tokyo.ac.jp) and I.K. (komuro-ky@umin.ac.jp)

32 **Abstract**

33

34 To understand the genetic underpinnings of atrial fibrillation (AF) in the Japanese population, we
35 performed a large-scale genome-wide association study comprising 9,826 cases of AF among
36 150,272 individuals and identified five new susceptibility loci, including East Asian-specific rare
37 variants. A trans-ancestry meta-analysis of >1 million individuals, including 77,690 cases, identified
38 35 novel loci. Leveraging gene expression and epigenomic datasets to prioritize putative causal
39 genes and their transcription factors revealed the involvement of *IL6R* gene and transcription factor
40 ERG besides the known ones. Further, we constructed a polygenic risk score (PRS) for AF, using the
41 trans-ancestry meta-analysis. PRS was associated with an increased risk of long-term cardiovascular
42 and stroke mortality, and segregated individuals with cardioembolic stroke in undiagnosed AF
43 patients. Our results provide novel biological and clinical insights into AF genetics and suggest their
44 potential for clinical applications.

45

46

47 Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting approximately
48 46.3 million individuals worldwide¹. The global prevalence of AF is increasing due to the rapid
49 aging of the general population and intensified search for subclinical AF². Despite progress in
50 diagnostic and therapeutic technologies, a substantial number of patients with AF are admitted with
51 life-threatening complications such as stroke and heart failure³, causing a considerable burden on
52 patients and public healthcare systems⁴. Besides conventional clinical risk factors such as ageing,
53 obesity, hypertension, and heart failure, the genetic contribution to the development of AF is also
54 widely recognized. Recent genome-wide association studies (GWASs) have identified more than 100
55 AF-associated loci, some of which are involved in cardiac developmental, electrophysiological,
56 contractile, and structural pathways⁵⁻⁸. However, since the vast majority of AF-GWASs have been
57 predominantly performed in European populations, the genetic pathophysiology of AF in non-
58 European populations has not been comprehensively understood and it is difficult to apply polygenic
59 risk scores (PRSs) derived from such GWASs to non-European populations.

60 Therefore, in the present study, we sought to explore the genetic architecture of AF in a
61 non-European population and improve the statistical power of AF-GWASs by performing a large-
62 scale Japanese GWAS, followed by conducting a trans-ancestry meta-analysis. Further, we
63 investigated the biological role of the identified AF-associated loci by leveraging gene expression
64 and epigenomic datasets. Additionally, we developed a PRS derived from the trans-ancestry meta-
65 analysis and assessed the impact of the PRS on relevant phenotypes and long-term mortality, which
66 may provide evidence for the clinical utility of AF-PRS and lay the foundation for the realization of
67 precision medicine in AF.

68 Results

69

70 Five novel loci for AF identified in the Japanese GWAS

71 An overview of the study design is shown in Supplementary Fig. 1. We performed a
72 GWAS on the case-control dataset from the BioBank Japan (BBJ) that comprised 9,826 AF cases
73 and 140,446 controls, using 16,394,105 variants in the autosomes and 423,039 variants in the X
74 chromosome with a minor allele frequency (MAF) > 0.1%. The GWAS identified 31 AF-associated
75 loci with genome-wide significance, of which five were previously unreported (Table 1,
76 Supplementary Table 1, Supplementary Fig. 2, and Supplementary Datasets 1 and 2). The proportion
77 of the variation in AF (the single nucleotide polymorphism (SNP) heritability; h^2) explained by the
78 total genome-wide genetic variation detected in the current Japanese GWAS was estimated to be
79 6.1% (standard error of mean [s.e.m.] 1.4%), and the liability-scale h^2 was estimated at 11.7%
80 (s.e.m. 2.6%) using linkage disequilibrium (LD)-score regression.

81 We found two novel loci whose lead variants were observed only in East Asian according
82 to the Genome Aggregation Database v2.1.1 (gnomAD)⁹: one low-frequency and one rare lead
83 variant, rs202030113 (MAF = 1.2%) and rs778479352 (MAF = 0.25%), respectively. The lead
84 variant on 6q25.1, rs202030113, was located in the intronic region three bases away from an exon-
85 intron boundary of *SYNE1* and was predicted as a splice donor loss with the spliceAI delta score of
86 0.33¹⁰. *SYNE1* encodes nesprin-1 (spectrin repeat) protein, and together with Sad1p/UNC84-domain-
87 containing proteins (SUN1/2), compose the nuclear envelope protein complex via its nucleoplasmic
88 domains to lamin A/C. Mutations in *LMNA* and *SYNE1* genes have been identified in patients with
89 severe muscle dystrophy and dilated cardiomyopathy^{11,12}. Mutations in the *SYNE1* gene cause
90 defects in nuclear morphology, myoblast differentiation, and heart development¹³, altering the
91 nuclear envelope protein complex that contributes to the structural substrate in atrial
92 arrhythmogenesis. A strong signal (odds ratio [OR] for AF development = 2.00, 95% confidence
93 interval [CI] = 1.73-2.31, $P = 1.6 \times 10^{-20}$) was displayed by rs778479352, the lead variant located in
94 an intron of *FGF13*. *FGF13* encodes a member of the fibroblast growth factor family, which

95 possesses broad mitogenic and cell survival activities. *FGF13* directly binds to the C-terminus of the
96 main cardiac sodium channel ($\text{Nav}1.5$) in the sarcolemma; knockdown of *FGF13* in rat
97 cardiomyocytes showed a loss of function of $\text{Nav}1.5$ -reduced Na^+ current density, decreased Na^+
98 channel availability, and slowed $\text{Nav}1.5$ -reduced Na^+ current recovery from inactivation¹⁴. This
99 evidence of conduction disturbance in cardiomyocytes indicates that *FGF13* is an important target
100 gene associated with AF.

101 To identify AF-associated variants independent of the lead variant at each locus, we
102 performed a stepwise conditional analysis, in which 18 independent variants (locus-wide $P < 5.0 \times 10^{-6}$)
103 were additionally detected, increasing the total number of AF-associated signals to 49
104 (Supplementary Fig. 3 and Supplementary Table 2). We identified 10 loci that had multiple
105 independent association signals, especially in the *PITX2-C4orf32* locus with 6 association signals
106 ($N_{\text{signal}} = 2$: *GORAB-PRRX1*, *CAND2*, *HAND2-AS1*, *FANCC*, *NEBL*, *AKAP6*, *ZFH3* loci, $N_{\text{signal}} = 3$:
107 *LINC02459-TBX5* locus, $N_{\text{signal}} = 4$: *NEURL1* locus, and $N_{\text{signal}} = 6$: *PITX2-C4orf32* locus). Of these
108 additional signals, three variants were observed only in East Asian populations in gnomAD
109 (rs577463446 at the *FANCC* locus, MAF = 0.5%, OR = 1.58; rs965277670 at *NEBL* locus, MAF =
110 0.6%, OR = 1.65; rs201901902 at *NEURL1* locus MAF = 0.5%, OR = 1.68).

111

112 **Sex-stratified GWAS for AF**

113 Sex-related differences in the epidemiology, clinical presentation, and prognosis of AF
114 have been consistently reported^{15,16}. For example, the age-stratified prevalence of AF is lower in
115 female than in male, despite a higher risk for AF-related outcomes such as stroke in female¹⁷⁻¹⁹.
116 Thus, we first performed sex-stratified GWAS and calculated the genetic correlation between sexes
117 using LD-score regression to explore the genetic heterogeneity. We then found a significant
118 correlation ($r_g = 1.095$, s.e.m. = 0.112, $P = 1.2 \times 10^{-22}$). Next, we examined genetic loci with sex-
119 dependent effects on AF development in the sex-stratified GWAS. We found 21 loci with genome-
120 wide significance in the male GWAS, but only six loci in the female GWAS (Supplementary Fig. 4a
121 and Supplementary Table 3). Furthermore, by comparing the effect sizes of the lead variants

122 identified in the sex-stratified GWAS, we observed significant positive correlation and concordant
123 allelic effects between sexes (Spearman's $\rho = 0.92$, $P = 7.4 \times 10^{-7}$; Supplementary Fig. 4b). We found
124 several variants with significant heterogeneity in the *PITX2-C4orf32* and *CUX2* loci ($P_{\text{het}} < 1.0 \times 10^{-}$
125 ⁴). Although the *PITX2-C4orf32* locus reached genome-wide significance in both sex-stratified
126 GWAS (β_{male} (s.e.m.-male) = 0.569 (0.018), $P_{\text{male}} = 1.9 \times 10^{-210}$; β_{female} (s.e.m.-female) = 0.381 (0.027),
127 $P_{\text{female}} = 3.0 \times 10^{-46}$, for rs12644625, the lead variant in the *PITX2-C4orf32* locus), the *CUX2* locus
128 in the female GWAS did not achieve genome-wide significance level (β_{male} (s.e.m.-male) = -0.280
129 (0.024), $P_{\text{male}} = 9.7 \times 10^{-33}$; β_{female} (s.e.m.-female) = -0.105 (0.034), $P_{\text{female}} = 2.1 \times 10^{-3}$, for rs12644625,
130 the lead variant in the *CUX2* locus). *CUX2* is a transcription factor regulating sex-biased gene
131 expression in rat and mouse liver^{20,21}, and the variant in the *CUX2* locus is associated with a DNA
132 methylation site near the *ALDH2* gene, encoding aldehyde dehydrogenase, which catalyzes the
133 oxidation of aldehydes into carboxylic acids²². Moreover, according to Genotype-Tissue Expression
134 (GTEx) data²³, *CUX2* gene expression in liver was significantly different between male and female
135 ($P = 7.8 \times 10^{-4}$, Wilcoxon rank-sum test; Supplementary Fig. 5). These results suggest that sex-
136 biased gene expression related to the metabolism of aldehydes in the liver may partially explain the
137 sex-related differences in the genetic basis of AF.

138

139 **Trans-ancestry meta-analysis identified 33 novel loci for AF**

140 To improve the statistical power to detect further genetic associations with AF, we
141 conducted a trans-ancestry meta-analysis by combining the current Japanese GWAS (BBJ) and two
142 European GWASs: a large-scale meta-analysis of European populations (EUR)⁷ and a biobank data
143 of FinnGen data release 2 (FIN). All three datasets yielded 77,690 cases (BBJ: 9,826; EUR: 60,620;
144 FIN: 7,244) and 1,167,040 controls (BBJ: 140,446; EUR: 970,216; FIN: 56,378). We tested a total of
145 5,158,449 variants with MAF $\geq 1\%$ and identified 150 AF-associated loci with genome-wide
146 significance (\log_{10} Bayes factor (BF) > 6 ; Fig. 1, Supplementary Table 4, and Supplementary
147 Datasets 3 and 4). Of these loci, 33 have not been reported previously, including three novel loci
148 detected in the current Japanese GWAS. In total, we identified 35 novel loci through the current

149 Japanese GWAS and trans-ancestry meta-analysis (Table 2).

150 Of the 5,855 variants in LD ($r^2 > 0.6$) with 150 lead variants, 27 missense variants were
151 observed (Supplementary Table 5). Among novel loci, we found a missense variant, rs848208
152 (p.Ala970Val), in the *SPEN* gene, encoding a hormone-inducible transcriptional co-regulator that
153 activates and represses downstream targets. *SPEN*-deficient zebrafish embryos developed
154 bradycardia, atrioventricular block, and heart chamber fibrillation with downregulation of connexin
155 43 expression²⁴, which is a well-known component of gap junctions and is associated with the
156 cardiac conduction system²⁵. Another missense variant in novel loci, rs3746471 (p.Arg1045Trp),
157 was located on the *KIAA1755* gene, which is reported to be associated with heart rate²⁶ and heart rate
158 variability²⁷. Given the robust relationship between autonomic nervous dysfunction and AF²⁸,
159 *KIAA1755* can be a potential target gene for neural modulation contributing to AF management;
160 however, the biological association between the *KIAA1755* gene and AF has not been fully
161 examined.

162

163 **Shared allelic effects between Japanese and European populations and fine mapping/credible** 164 **set analyses in the trans-ancestry meta-analysis**

165 We compared alternate allele frequencies and allelic effects for 150 lead variants between
166 BBJ, EUR, and FIN. Compared to substantial concordance in allele frequencies between EUR and
167 FIN (Spearman's $\rho = 0.974$, $P < 2.2 \times 10^{-16}$), we observed a moderate correlation in allele
168 frequencies between BBJ and EUR as well as BBJ and FIN ($\rho = 0.592$, $P = 1.5 \times 10^{-15}$ and $\rho =$
169 0.632 , $P < 2.2 \times 10^{-16}$, respectively; Supplementary Fig. 6a-c). Additionally, we found a significant
170 positive correlation between concordant allelic effects of these variants ($\rho = 0.769$, $P < 2.2 \times 10^{-16}$
171 for BBJ vs. EUR; $\rho = 0.769$, $P < 2.2 \times 10^{-16}$ for BBJ vs. FIN; Supplementary Fig. 6d-f). To further
172 explore the relationship of allelic effects between populations, we performed a trans-ancestry genetic
173 correlation analysis, which showed strong correlation of BBJ with EUR and FIN (BBJ and EUR: r_g
174 $= 0.990$, s.e.m. = 0.097, BBJ and FIN $r_g = 0.955$, s.e.m. = 0.344).

175 To assess the contribution of trans-ancestry meta-analyses to the refinement of the

176 putative causal variants, we constructed 99% credible sets for the 150 AF-associated loci detected by
177 the current trans-ancestry meta-analysis, and compared the number of variants included in the 99%
178 credible sets derived from three combinations of the meta-analysis (EUR + BBJ, EUR + FIN, BBJ +
179 EUR + FIN; Supplementary Fig. 6g, h). The size of the 99% credible sets derived from EUR + BBJ
180 significantly decreased compared with those from EUR + FIN ($P = 0.004$, paired Wilcoxon rank-
181 sum test). In addition, trans-ancestry meta-analysis of three datasets (BBJ + EUR + FIN) yielded the
182 most significant decrease in the number of variants among all the combinations of meta-analyses
183 (median number of variants = 12; interquartile range [IQR] 5 – 36; Supplementary Table 6). In
184 particular, a single variant, rs67329386, was identified on the *ZFHX3* locus with a high posterior
185 probability of 0.995, only in the trans-ancestry meta-analysis of three datasets. In previous AF-
186 GWAS, several variants were found in the *ZFHX3* locus^{29,30}, where a large transcription factor,
187 *ZFHX3*, together with *PITX2*, facilitated DNA binding and transcription activity³¹. To corroborate
188 the role of rs67329386 as a causal variant, we searched for transcription factors binding to this locus
189 using the ChIP-seq dataset in ChIP-Atlas³². Compared to other AF-associated variants within this
190 locus, rs67329386 was distinctly located on the binding site of CEBPB (Supplementary Fig. 7),
191 aiding in the recognition and binding of target gene regulatory regions, leading to cell proliferation,
192 differentiation, immune response, and tumor formation³³.

193

194 **Pleiotropic effects and functional pathways of AF-associated loci**

195 To characterize the AF-associated loci, we examined the pleiotropic effects of the
196 identified lead variants and proxies using the NHGRI-EBI GWAS catalog database. Of the 150 AF-
197 associated loci, 114 (76.0%) had at least one overlapping variant, and 739 variants overlapped with
198 200 diseases or traits (Supplementary Table 7). Among them, blood pressure-related traits were most
199 frequently observed (13.0%), followed by traits related to electrocardiogram (10.1%) and heart rate
200 (4.0%).

201 Given the heterogeneous study design and population in the GWAS catalog, we
202 subsequently utilized the BBJ dataset³⁴⁻³⁶ with a consistent study design and population, to

203 investigate the pleiotropic effects. In particular, to explore the biological pathways related to AF
204 development, we searched for AF-associated variants overlapping with quantitative trait loci (QTL)
205 for clinical measurements such as anthropometric, metabolic, kidney-related, and blood pressure
206 data (Supplementary Table 8). We found 160 loci-phenotype association pairs, where distinct
207 functional clusters were observed (Supplementary Fig. 8); positive impact on blood pressure:
208 *CASZ1*, *PRDM8-FGF5*, *CUX2*, and *RPH3A*, and negative impact on renal function: *MIR5096*,
209 *MBD5*, *DNAJC12-SIRT1*, *IGF1R*, and *NFATC1*. Moreover, we observed associations on
210 chromosome 6p21.31 harboring *HMGAI*, in which AF-associated variants overlapped with QTLs for
211 height (rs1759628) and body mass index (BMI) (rs6913361). Both rs1759628 and rs6913361 were
212 located 7 kilobases (kb) and 25 kb upstream of *HMGAI*, respectively, and the risk alleles of these
213 variants were significantly associated with increased height and BMI (β_{height} (s.e.m.height) = 0.090
214 (0.005), $P_{\text{height}} = 8.7 \times 10^{-93}$; β_{BMI} (s.e.m.BMI) = 0.037 (0.005), $P_{\text{BMI}} = 1.7 \times 10^{-12}$, respectively).
215 *HMGAI* encoded a chromatin-associated protein that attach to AT-rich regions of DNA and recruit
216 transcription factors, resulting in upregulation of the insulin receptor gene expression³⁷ and the
217 variants in *HMGAI* were associated with increased risk of metabolic syndrome³⁸.

218 To enhance the biological understanding of the AF-associated loci, we performed in
219 silico tissue and gene-set enrichment analysis using DEPICT software³⁹, which prioritizes candidate
220 genes and tissues based on gene expression data from different tissues and cell types. Consistent
221 with a previous study⁷, we found significant enrichment of AF-associated loci predominantly in
222 heart tissues ($P < 1.2 \times 10^{-5}$ for heart and $P < 2.3 \times 10^{-5}$ for heart atria; Supplementary Fig. 9 and
223 Supplementary Table 9). Additionally, pathway analysis demonstrated that AF-associated loci were
224 significantly enriched in 34 out of 1,157 gene sets, most of which were involved in heart
225 development and morphogenesis (Supplementary Table 10). Among them, the regulation of cell
226 adhesion was a previously unreported pathway ($P = 1.6 \times 10^{-10}$), in which *ZMIZ1*, the nearest gene
227 for rs1769758, was reported to regulate the activity of various transcription factors related to
228 vascular development, androgen receptor coregulation, SMAD3 regulation, and coactivation of
229 p53⁴⁰⁻⁴². Knockdown of *ZMIZ1* in mice resulted in severe defects in the reorganization of the yolk

230 sac vascular plexus and cell proliferation⁴³.

231

232 **Prioritization of AF-associated genes and transcription factors using gene expression and**
233 **epigenetic features**

234 We performed a transcriptome-wide association study (TWAS) using the identified loci
235 in the trans-ancestry meta-analysis and GTEx data²³ to identify candidate genes associated with AF.
236 Given the enrichment of AF-associated loci in the heart tissue, we used the gene expression data of
237 GTEx in the atrial appendage and left ventricle as a reference. TWAS prioritized 86 and 74 candidate
238 causal genes significantly associated with AF in the atrial appendage and left ventricle, respectively
239 (Fig. 2a and Supplementary Table 11). We found only 14 and 15 overlapping genes between nearby
240 genes located on the AF-associated loci and the candidate genes in the atrial appendage and left
241 ventricle, respectively (Fig. 2b). Moreover, the median physical distances from the lead variants to
242 the candidate genes were greater than 100 kb. Notably, 17.4% and 25.6% of the candidate genes
243 were located 500 kb away from the lead variants (Fig. 2c). Further, to test whether the candidate
244 genes were enriched in unique pathways, we used ingenuity pathway analysis and found several
245 canonical pathways, including fatty acid metabolism-related pathways, in which the candidate genes
246 prioritized in both atrial appendage and left ventricle were enriched (Fig. 2d). Intriguingly, *IL6R* was
247 identified as a candidate gene associated with AF in the atrial appendage and was also involved in
248 the canonical associated pathway. Despite increasing evidence for the role of inflammation in the AF
249 pathophysiology⁴⁴, including a report on the suggestive association of the *IL6R* locus with AF ($P =$
250 5.0×10^{-4})⁴⁵, the genetic contribution of inflammatory process to AF development has not been fully
251 elucidated. Our transcriptome-wide analysis revealed a significant association between *IL6R* and AF
252 development, providing supportive evidence for the contribution of inflammation through *IL6R* to
253 the pathophysiological mechanism underlying AF.

254 Next, we sought to identify transcription factors that bind to AF-associated loci which
255 orchestrate the expression of causative genes involved in AF development. We performed
256 enrichment analysis using the ChIP-Atlas³² dataset, which comprised several high-throughput ChIP-

257 seq experiments (15,109 experiments, 1,028 transcription factors). As a result, AF-associated loci
258 were characterized by enriched binding of 33 distinct transcription factors ($P < 0.05$) in
259 cardiovascular cells, pluripotent stem cells-derived cardiac cells, and muscle cells (Fig. 3a and
260 Supplementary Table 12). Of these, ERG, TAL1, and TBX5 were among the top enriched
261 transcription factors and are known to be involved in endothelial gene expression and
262 differentiation^{46,47}. In particular, ERG binding was significantly enriched with Bonferroni-corrected
263 significance level of $P = 3.3 \times 10^{-6}$ ($0.05/15,109$): ERG ChIP-seq peaks overlapped with AF-
264 associated loci around genes encoding cardiac ion channels (*SCN10*, *KCNH2*, *HCN4*, and
265 *CAMK2D*), where active histone markers such as H3K27ac and H3K4me3 in induced pluripotent
266 stem cells (iPSC)-derived cardiac cells were also observed (Fig. 3b and Supplementary Fig. 10).
267 These results suggest that ERG is a transcription factor that regulates the expression of AF-
268 associated genes.

269

270 **Predictive ability of PRS derived from single-population GWAS and trans-ancestry meta-** 271 **GWAS**

272 PRS has the potential for risk stratification of complex traits and diseases based on
273 genetic data. However, the transferability of PRS from diverse populations to a population of another
274 ancestry remains challenging. Therefore, we examined the performance of a PRS derived from
275 various combinations of summary statistics in the Japanese population. We split our case-control
276 samples into derivation, validation, and test datasets, and constructed 255 combinations of the
277 summary statistics of three GWAS studies (BBJ, EUR, and FIN) and parameters for PRS derivation.
278 Based on the PRS performance in the validation cohort, we determined the parameters that showed
279 the best performance for each combination of summary statistics (BBJ, FIN, EUR, BBJ + FIN, BBJ
280 + EUR, EUR + FIN, and BBJ + EUR + FIN) (Supplementary Table 13), and assessed the
281 performance of the best model in the test cohort (Fig. 4, Supplementary Fig. 11, and Supplementary
282 Table 14). Concordant with the population specificity, the PRS derived from BBJ showed a
283 significantly better performance than those from European studies ($P < 2.2 \times 10^{-16}$ for both BBJ vs.

284 EUR and BBJ vs. FIN). Furthermore, the performance of the PRS derived from meta-analysis that
285 included different ancestry groups (EUR + BBJ and FIN + BBJ) significantly exceeded that from a
286 single study ($P < 2.2 \times 10^{-16}$ for all cases) as well as that from a meta-analysis of two European
287 studies ($P < 2.2 \times 10^{-16}$ for both EUR + BBJ vs. EUR + FIN and BBJ vs. FIN + EUR). Among all
288 models, the PRS derived from three studies with multi-ancestry and the largest sample size (BBJ +
289 EUR + FIN) showed the highest performance (pseudo $R^2 = 0.144$, 95% CI = 0.130–0.154, area
290 under the curve of receiver operating characteristic = 0.737, 95% CI = 0.726–0.748).

291

292 **Impact of AF-PRS on AF-relevant phenotypes and cardiovascular outcomes**

293 To assess the potential for clinical applications of the PRS, we investigated the
294 association between PRS and the onset age of AF in individuals from our BBJ case samples ($n =$
295 7,459). We observed that the onset age decreased as the PRS increased, and individuals with the top
296 1% PRS were estimated to be approximately 4 years younger in AF onset compared to the remaining
297 individuals (Fig. 5a, 5b, and Supplementary Fig. 12a). Next, we examined whether AF-PRS could
298 explain the phenotypic variability of stroke in individuals without a diagnosis of AF. We performed
299 logistic regression analysis in 140,446 control samples in our dataset, and found significant
300 associations of the PRS with increased risks of cerebral infarction (OR [95% CI] = 1.055 [1.032 –
301 1.078], $P = 1.2 \times 10^{-6}$), cardioembolic stroke (OR [95% CI] = 1.391 [1.155 – 1.676], $P = 5.2 \times$
302 10^{-4}), atherothrombotic stroke (OR [95% CI] = 1.054 [1.001 – 1.111], $P = 0.045$), and cerebral
303 hemorrhage (OR = 1.068, 95% CI = 1.008 – 1.133, $P = 0.027$; Fig. 5c). Importantly, we observed the
304 largest impact of the PRS on cardioembolic stroke among those with other stroke phenotypes,
305 indicating that AF-PRS may reveal clinically undetectable AF (i.e., subclinical AF) or AF-related
306 conditions, such as prothrombotic or hypercoagulable state, in individuals without AF.

307 To further explore the clinical utility of AF-PRS, we assessed the impact of PRS on
308 mortality using long-term follow-up data in the BBJ. The Kaplan-Meier estimates of cumulative
309 mortality rate were increased in individuals with a high PRS, especially in cardiovascular- and
310 stroke-related mortality (Fig. 5d and Supplementary Fig. 12b). Cox regression analysis demonstrated

311 that PRS was significantly associated with an increased risk of cardiovascular death (hazard ratio
312 [HR] per 1 standard deviation [s.d.] of PRS = 1.06, 95% CI = 1.02–1.11, $P = 5.0 \times 10^{-3}$) and stroke
313 death (HR [95% CI] = 1.14 [1.04–1.24], $P = 4.0 \times 10^{-3}$; Fig. 5e). In contrast to evidence from
314 clinical studies, the association between PRS and heart failure death did not reach statistical
315 significance in the present study (HR [95% CI] = 1.05 [0.95–1.16], $P = 0.39$), because the statistical
316 power might be hampered by a small fraction of heart failure deaths with relatively wide dispersion
317 in our cohort.

318

319 **Genetic liability of AF to various cardiovascular diseases**

320 AF is frequently associated with various cardiovascular diseases, such as valvular heart
321 disease, heart failure, and stroke. The causal relationship between AF and cardiovascular diseases is
322 clinically evident, but genetic causality is not comprehensively understood. Therefore, we estimated
323 the directional effect of AF on a wide range of cardiovascular diseases using two-sample Mendelian
324 randomization (MR), where the exposure was AF and all the distinct AF-associated variants from the
325 trans-ancestry meta-analysis were used as instrumental variables. Consistent with clinical evidence,
326 we observed significant causal effects on heart failure, cardiomyopathy, ischemic heart disease,
327 valvular heart disease, and stroke (Fig. 6 and Supplementary Table 15). Notably, we found that AF
328 was a significant predictor for sinus node dysfunction and atrioventricular block (OR [95% CI] =
329 1.480 [1.255–1.745], $P = 3.0 \times 10^{-6}$; OR [95% CI] = 1.253 [1.167–1.346], $P = 6.1 \times 10^{-10}$,
330 respectively), indicating that genetic risk for AF contributes to the potential disturbance in the
331 cardiac conduction system.

332 In contrast, AF is also known as the phenotype accumulated by multiple atherosclerotic-
333 and metabolic-related traits. Therefore, we investigated whether genetic risks for such traits could
334 affect the development of AF using two-sample MR, where the exposures represented quantitative
335 traits, and selected the distinct variants associated with each trait as instrumental variables. As
336 expected⁴⁸, height and BMI were significant predictors for AF (OR [95% CI] = 1.381 [1.166–1.635],
337 $P = 1.8 \times 10^{-4}$; OR [95% CI] = 1.160 [1.099–1.225], $P = 7.6 \times 10^{-8}$, respectively). Furthermore,

338 blood pressure showed a significant causal effect on AF (OR [95% CI] = 1.383 [1.292–1.480], $P =$
339 9.4×10^{-21} for systolic blood pressure; OR (95% CI) = 1.393 (1.298–1.494), $P = 2.9 \times 10^{-20}$ for
340 diastolic blood pressure; OR (95% CI) = 1.220 (1.131–1.317), $P = 3.0 \times 10^{-7}$ for pulse pressure;
341 Supplementary Fig. 13 and Supplementary Table 15).

342 **Discussion**

343

344 We conducted a large-scale AF-GWAS with approximately 10,000 AF cases in the
345 Japanese population and identified 31 genome-wide significant loci associated with AF. This
346 includes five novel loci, where disease-relevant rare and highly East Asian-specific variants were
347 found in the *SYNE1* and *FGF13* loci, suggesting the involvement of the functional alteration in the
348 nuclear envelope and the ion channel as a mechanism underlying AF.

349 Furthermore, we performed the largest trans-ancestry meta-analysis for AF to date, where
350 150 genome-wide significant loci were identified, resulting in the discovery of 35 novel loci.

351 We further analyzed AF-associated genes and transcription factors using gene expression and
352 epigenetic datasets. Transcriptome-wide analysis linked AF-associated loci to target genes, including
353 *IL6R*, which indicated that inflammation plays a key role in the pathogenesis of AF. Additionally, our
354 approach based on the ChIP-seq dataset clearly implicated ERG as a candidate transcription factor
355 involved in the regulation of AF-associated gene expression. ERG is highly expressed in endothelial
356 cells and regulates a wide range of targets and pathways involved in vascular homeostasis and
357 angiogenesis⁴⁹. Endothelial dysfunction is observed in patients with AF^{50,51}, but the association
358 between AF and ERG had not been previously examined. This may be attributable to mutational
359 constraints on the ERG gene according to the relatively low LOEUF score of 0.33 in gnomAD and
360 embryonic lethality in ERG knockout mice with severe defects in vascular development^{52,53}.

361 Although the contribution of ERG signaling to AF development needs further confirmation by
362 functional experiments, the results from this study suggest that ERG may play a critical role in the
363 pathophysiology of AF through vascular development at early developmental stages.

364 We found shared allelic effects of lead variants in AF-associated loci and genetic
365 correlations between Japanese and European populations. We then derived AF-PRS from the trans-
366 ancestry meta-analysis, which outperformed that derived from a population-specific GWAS. In
367 addition to the predictive ability for AF itself, AF-PRS segregated individuals with AF-related
368 phenotypes, such as early onset of AF and cardioembolic stroke, as well as those with increased risks

369 of long-term cardiovascular and stroke mortalities. These results indicated that the cumulative
370 genetic risk for AF may be an indicator for early therapeutic intervention, including anticoagulation
371 in at-risk individuals as a primary prevention of stroke. Taken together, our findings suggest the
372 clinical utility of AF-PRS for individual risk stratification, leading to the realization of future
373 precision medicine.

374 In conclusion, our large-scale Japanese and trans-ancestry genetic analyses identified 35
375 novel loci and provided insights into the distinct and shared genetic architecture of AF between
376 Japanese and Europeans. Integrative analysis of transcriptome and epigenome data revealed the
377 candidate genes and transcription factors involved in the mechanism of disease development.
378 Furthermore, analyses of disease prediction and long-term survival demonstrated the clinical utility
379 of the AF-PRS. These data highlight the importance of AF genetics in clinical settings and provide
380 useful evidence for the implementation of genomic medicine.

381

382

383 **Methods**

384

385 **Study populations**

386 All subjects were Japanese who were registered in the BioBank Japan (BBJ) project
387 (<https://biobankjp.org/>). The BBJ is a hospital-based national biobank project that collects DNA and
388 serum samples and clinical information from 12 cooperative medical institutes throughout Japan
389 (Osaka Medical Center for Cancer and Cardiovascular Diseases, Cancer Institute Hospital of
390 Japanese Foundation for Cancer Research, Juntendo University, Tokyo Metropolitan Geriatric
391 Hospital, Nippon Medical School, Nihon University School of Medicine, Iwate Medical University,
392 Tokushukai Hospitals, Shiga University of Medical Science, Fukujuji Hospital, National Hospital
393 Organization Osaka National Hospital, and Iizuka Hospital). Approximately 200,000 patients with
394 any of the 47 target diseases were enrolled between 2003 and 2007. All samples were at least 18
395 years old. Informed consent was obtained from all participants, and our study was approved by the
396 relevant ethical committees at each facility.

397 For the quality control of GWAS, we excluded samples with a call rate < 0.98 and related
398 individuals with $PI_HAT > 0.2$, which is an index of relatedness based on pairwise identity-by-
399 descent implemented in PLINK 2.0 (20 Aug 2018 ver.). We then excluded samples with a
400 heterozygosity rate $> +4$ s.d. To identify population stratification, we performed principal component
401 analysis using PLINK 2.0. and excluded outliers from the Japanese cluster. For the case samples in
402 GWAS, we selected individuals with atrial fibrillation or atrial flutter diagnosed by a physician based
403 on general medical practices or documented on a 12-lead electrocardiogram. The demographic
404 features of the case–control cohort are shown in Supplementary Table 16.

405

406 **Genotyping, imputation, and quality control**

407 GWAS subjects were genotyped using the Illumina Human OmniExpress Genotyping
408 BeadChip or a combination of Illumina HumanOmniExpress and HumanExome BeadChips
409 (Illumina, San Diego, CA). For genotype quality control, we excluded variants with (i) SNP call rate

410 < 0.99, (ii) MAF < 0.01, and (iii) Hardy–Weinberg equilibrium P value $\leq 1.0 \times 10^{-6}$. We pre-phased
411 the genotypes using EAGLE and imputed dosages with the 1,000 Genome Project Phase 3 (1KG
412 Phase 3; May 2012)⁵⁴ reference panel with 1,037 Japanese in-house reference panel from BBJ using
413 minimac3. For the X chromosome, pre-phasing was performed in both males and females, and
414 imputation was performed separately for males and females. Dosages of variants in X chromosomes
415 for males were assigned between 0 and 2.

416

417 **GWAS**

418 In the Japanese GWAS, association was performed by logistic regression analysis
419 assuming an additive model with adjustment for age, age², sex, and top 20 principal components
420 using PLINK 2.0. We selected variants with minimac3 imputation quality score of > 0.3 and MAF \geq
421 0.001. For the X chromosome, we conducted association analyses in males and females separately,
422 and integrated the results using an inverse-variance weighted fixed-effects model implemented in
423 METASOFT (v2.0.1). Heterogeneity between studies was calculated using the Cochran’s Q test. We
424 filtered variants with strong heterogeneity ($P_{het} < 1.0 \times 10^{-4}$). The genome-wide significance
425 threshold was defined at $P < 5.0 \times 10^{-8}$ for variants with MAF $\geq 1\%$ and $P < 5.71 \times 10^{-9}$ for those
426 with MAF < 1% (0.05/8,753,038 variants). Although the genomic inflation factor (λ_{GC}) was 1.12,
427 LD-score regression indicated that the inflation was primarily due to polygenic effects (LD-score
428 regression intercept = 1.02; Supplementary Fig. 14a). Adjacent genome-wide significant SNPs were
429 grouped into one locus if they were within 1 Mb from each other. We defined a locus as the
430 candidate region that was located within 500 Mb upstream and downstream of the genome-wide
431 significant variants. When a locus was not in LD ($r^2 < 0.10$) with reported loci, we defined it as a
432 novel locus. In sex-stratified association analysis of 81,050 males (6,825 cases and 74,225 controls)
433 and 69,222 females (3,001 cases and 66,221 controls), we also performed logistic regression analysis
434 in males and females separately using the same pipeline as described above. To investigate the
435 difference in genetic susceptibility to AF between males and females, we compared effect sizes of
436 the variants identified in the sex-stratified GWAS. Genotyped or imputed variants were annotated

437 using ANNOVAR (7 July 2017 build) (<http://annovar.openbioinformatics.org>).

438

439 **Stepwise conditional analysis**

440 To identify independent association signals in the loci, we conducted a stepwise
441 conditional analysis for genome-wide significant loci defined as described in the GWAS. First, we
442 performed logistic regression conditioning on the lead variants of each locus. We set a locus-wide
443 significance at $P < 1.0 \times 10^{-5}$ and repeated this procedure until none of the variants reached locus-
444 wide significance for each locus.

445

446 **LD score regression and heritability**

447 To estimate confounding biases such as cryptic relatedness and population stratification,
448 we performed an LD score regression (Version 1.0.0). We selected SNPs with $MAF \geq 0.01$, and
449 variants within the major histocompatibility complex region were excluded. For the regression, we
450 used the East Asian LD scores provided by the authors (<https://github.com/bulik/ldsc/>).

451

452 **Trans-ancestry meta-analysis**

453 Summary results from two European AF GWASs (EUR and FIN) were obtained from a
454 previously published website (<http://csg.sph.umich.edu/willer/public/afib2018>)⁷ and from the
455 FinnGen research project website (<https://www.finnngen.fi/en>), respectively. EUR is a meta-analysis
456 of six contributing AF data sources (The Nord-Trøndelag Health Study, deCODE, the Michigan
457 Genomics Initiative, DiscovEHR, UK Biobank, and the AFGen Consortium). FIN is composed of
458 102,739 Finnish participants, and the phenotypes were derived from ICD codes in Finnish national
459 hospital registries and cause-of-death registry as a part of the FinnGen project. To inspect the biases
460 of these GWAS, we calculated the LD-score regression intercept for each study and confirmed that
461 these two studies were well calibrated (LD score regression intercept for EUR = 1.052 (s.e.m. =
462 0.012) and FIN = 1.033 (s.e.m. = 0.010); Supplementary Fig. 14b, c). We also calculated the genetic
463 correlation and found a significant genetic correlation between EUR and FIN ($r_g = 0.918$, s.e.m. =

464 $0.035, P = 3.9 \times 10^{-155}$).

465 To account for the ancestral heterogeneity among the three studies, we applied the
466 MANTRA algorithm in the trans-ancestry meta-analysis⁵⁵, which allows for heterogeneity between
467 diverse ancestry groups and improves performance compared to fixed-effects meta-analysis and
468 random-effects meta-analysis. Variants with MAF $\geq 1\%$ in both the Japanese and European
469 populations were selected for association. We considered SNPs with $\log_{10} BF > 6$ to be genome-wide
470 significant.

471

472 **Trans-ancestry genetic correlation**

473 To estimate the trans-ancestry genetic correlation, we applied Popcorn software (v.1.0).
474 We used East Asia or European samples of 1KG for the LD reference and excluded the variants
475 within the major histocompatibility complex region according to the instructions of the software. To
476 estimate the liability-scale genetic correlation, we assumed that the AF prevalence was 0.58% in the
477 Japanese population, 1.38% in the United Kingdom population, and 0.97% in the Finnish population
478 (<https://vizhub.healthdata.org/gbd-compare/>).

479

480 **Credible set analysis**

481 To construct sets of variants that likely include causal variants, we constructed a 99%
482 credible set in each AF-associated locus using BF obtained from MANTRA results in the trans-
483 ancestry meta-analysis. For each locus, we calculated the posterior probability (PP) for the j^{th} SNP
484 using the following formula: $PP_j = \frac{BF_j}{\sum_k BF_k}$, where BF_j denotes the BF for the j^{th} SNP and BF_k
485 denotes all of the variants included in the locus. We then constructed the 99% credible set by adding
486 the variants in order of decreasing PP until the cumulative PP reached 0.99. To assess whether the
487 99% credible set derived from the trans-ancestry meta-analysis narrowed down the causal variants,
488 we performed two additional meta-analyses (EUR + BBJ and EUR + FIN) using the MANTRA
489 algorithm and constructed 99% credible sets for 150 AF-associated loci identified by the trans-
490 ancestry meta-analysis. We then compared the number of variants in the 99% credible set for each

491 locus. Among them, the loci where at least one variant surpassed genome-wide significance (\log_{10}
492 $BF > 6$) in all meta-analyses were included in the test. The differences in the sizes of the credible
493 sets were tested using the paired Wilcoxon rank-sum test.

494

495 **Pleiotropy**

496 We searched for AF-associated variants that overlapped with other diseases or traits using
497 the NHGRI-EBI GWAS catalog on February 8, 2019. As reported previously³⁴, we selected the AF-
498 associated variants in the trans-ancestry meta-analysis according to the following criteria: (i) variants
499 with $r^2 > 0.5$ in both East Asian and European samples of 1KG if the publication in GWAS catalog
500 included East Asians, (ii) variants with $r^2 > 0.5$ in European samples of 1KG if the original report
501 did not study East Asian populations; and (iii) the physical distance from AF-associated lead variants
502 in the trans-ancestry meta-analysis to variants reported in the GWAS catalog was within 25 kb.

503 For the association analysis between AF-associated loci and QTL for clinical parameters,
504 we used the summary statistics previously reported in the BBJ dataset³⁴⁻³⁶. We selected AF-
505 associated variants ($r^2 > 0.6$ in East Asian samples of 1KG and clinical parameters of nine distinct
506 categories: anthropometric (n=2), metabolic (n=6), serum protein (n=2), kidney-related (n=4),
507 electrolyte (n=3), liver-related (n=5), other biochemical (n=5), hematological (n=5), and blood
508 pressure (n=4). In QTL analysis, clinical measurements were corrected by taking into account the
509 effect of medications as follows: for individuals taking cholesterol-lowering drugs, total cholesterol
510 and low-density-lipoprotein cholesterol levels were corrected by dividing by 0.8 and 0.7,
511 respectively³⁵; for individuals taking antihypertensive drugs, 15 mmHg was added to the systolic
512 blood pressure and 10 mmHg to the diastolic blood pressure readings³⁵. Furthermore, linear
513 regression models for these quantitative traits were adjusted for sex, age, age², the top 10 principal
514 components, and disease status. Smoking status was also introduced into the model for white blood
515 cell count and C-reactive protein levels. We chose QTL showing a genome-wide significant
516 association ($P < 5.0 \times 10^{-8}$).

517

518 **Tissue and gene set enrichment analysis**

519 For tissue and gene set enrichment analysis, we used data-driven expression-prioritized
520 integration for complex traits (DEPICT) software (<https://data.broadinstitute.org/mpg/depict>)³⁹. To
521 reduce the redundancy of the pathways, we applied affinity propagation clustering implemented in
522 the aplcluster package v.1.4.8 in R^{56,57}. Using this algorithm, we obtained distinct clusters that
523 contained ‘exemplar’ pathway and member pathways. We extracted 48 exemplar tissues and 1,157
524 gene sets for enrichment analysis and selected independent AF-associated variants with $\log_{10} BF > 5$
525 as applied in a previous study⁵⁸. The significance level was set at $P = 1 \times 10^{-3}$ ($=0.05/48$) for tissue
526 enrichment analysis and $P = 4.3 \times 10^{-5}$ ($=0.05/1,157$) for gene set enrichment analysis.

527

528 **Transcriptome-wide association study**

529 We performed a transcriptome-wide association study to assess gene-AF associations
530 using MetaXcan v0.3.512⁵⁹, which estimates the association between predicted gene expression
531 levels and a phenotype of interest using summary statistics and gene expression prediction models.
532 We used precomputed prediction models with LD reference data in GTEx v7 for atrial appendage
533 and left ventricular tissues and the summary statistic of the trans-ancestry AF-GWAS as input.
534 Bonferroni significance level was set at $P = 8.4 \times 10^{-6}$ ($=0.05/5,988$) for atrial appendage and $P = 9.3$
535 $\times 10^{-6}$ ($=0.05/5,378$) for left ventricle to account for the number of genes tested in each tissue.

536

537 **Enrichment analysis of transcription factor**

538 To assess the enrichment of transcription factor in AF-associated loci, we defined AF-
539 associated loci as regions within 500 Mb upstream and 500 Mb downstream of the AF-associated
540 lead variants or proxies with $r^2 > 0.8$ in European samples of 1KG. We then searched for overlaps of
541 peak-call data archived in the ChIP-Atlas dataset with AF-associated loci and control regions
542 selected from all the genome regions by permutation test. P -values were calculated with the two-
543 tailed Fisher’s exact probability test (the null hypothesis is that the two regions overlap with the
544 ChIP-Atlas peak-call data in the same proportion). The epigenetic landscapes around cardiac ion

545 channel-related genes were visualized using ChIP-Atlas Peak Browser and Integrative Genomics
546 Viewer⁶⁰.

547

548 **PRS derivation and performance**

549 We derived PRS using the pruning and thresholding methods. PRSs were created over a
550 range of P value threshold (0.5 , 5.0×10^{-2} , 5.0×10^{-4} , 5.0×10^{-6} , and 5.0×10^{-8}) and r^2 threshold
551 (0.2 , 0.5 , and 0.8). For the survival analysis, we divided our dataset into three groups: (i) a discovery
552 group to derive and validate PRS (6,890 cases and 49,451 controls), (ii) a test group to assess PRS
553 performance (2,953 cases and 21,194 controls), and (iii) a group for the survival analysis (70,645
554 controls) (Supplementary Fig. 15). To secure independence between the PRS derivation and
555 validation, we used a ten-fold cross-validation approach. First, we randomly split a discovery group
556 into ten subgroups and used nine of these subgroups for PRS derivation and the remaining one for
557 PRS validation. To determine the weight of PRS, we performed GWAS in combination with two
558 European GWAS: (i) Japanese subgroup GWAS, (ii) two European GWAS (EUR or FIN), (iii)
559 Japanese subgroup GWAS + EUR (fixed- or random-effect model), (iv) Japanese subgroup GWAS +
560 FIN (fixed- or random-effect model), (v) EUR + FIN (fixed- or random-effect model, and (vi)
561 Japanese subgroup GWAS + EUR + FIN (fixed- or random-effect model). Meta-analyses were
562 performed using the METASOFT software. In the meta-analysis with the Japanese subgroup GWAS,
563 LD was calculated separately based on East Asian or European samples of 1KG. We then calculated
564 the PRSs for the withheld validation cohort using PLINK 2.0 and validated its performance.
565 Changing the withheld validation cohort, we repeated these procedures ten times and obtained the
566 performance measurements for each combination. Notably, the validation cohort was excluded from
567 the derivation of GWAS. The performance of the PRS was measured as (1) Nagelkerke's pseudo R^2
568 obtained by modeling age, sex, and normalized PRS, and (2) the area under the curve of the receiver
569 operator curve in the same model as Nagelkerke's pseudo R^2 . The best model/parameter set for each
570 combination model (BBJ, EUR, FIN, BBJ + EUR, BBJ + FIN, EUR + FIN, BBJ + EUR + FIN) was
571 determined by averaging Nagelkerke's pseudo R^2 (Supplementary Table 13). Using the best models

572 and parameters determined in the derivation and validation cohorts, we calculated the PRSs and
573 assessed their performance for the independent test cohort. We applied bootstrapping to assess the
574 distribution of performance of the PRS; randomly extracted the individuals in the test cohort with
575 replacement and calculated the performance for the samples. By repeating this procedure 5.0×10^4
576 times, we estimated the distribution of the performance measures.

577

578 **Association of AF-PRS with age of AF onset and stroke subtypes**

579 To assess the association between AF-PRS and age at AF onset, we extracted AF case
580 samples with the data ($n = 7,458$, median age of AF onset was 63 years of age (IQR 56 – 71)), and
581 estimated the difference in the effect of AF onset age between individuals with top PRS to those with
582 the remaining PRS using a linear regression model adjusted for sex and top 10 principal
583 components. For the association analysis between AF-PRS and stroke subtype, we calculated ORs
584 and associated P values using a logistic regression model adjusted for age, sex, and the top 10
585 principal components. Among the control samples (without AF diagnosis) in our dataset ($n =$
586 140,447), we found 14,120 stroke phenotypes: 9,177 for cerebral infarction, 111 for cardioembolic
587 stroke, 1,465 for atherothrombotic infarction, 1,266 for lacunar infarction, 1,143 for cerebral
588 hemorrhage, and 967 for subarachnoid hemorrhage.

589

590 **Survival analysis**

591 For survival analysis, the Cox proportional hazards model was used to assess the
592 association between AF-PRS and long-term mortality. We obtained survival follow-up data with the
593 ICD-10 code for 132,737 individuals from the BBJ dataset^{61,62}. The causes of death were classified
594 according to ICD-10 codes: (i) cardiovascular death (I00–I99), (ii) heart failure death (I50), (iii)
595 ischemic heart disease death (I20–I25), and (iv) stroke death (I60, I61, I63, and I64). The median
596 follow-up period was 8.4 years (IQR 6.8 – 9.9). The Cox proportional hazards model was adjusted
597 for sex, age, top 10 principal components, and disease status. Analyses were performed with the R
598 package survival v.2.44, and survival curves were estimated using the R package survminer v.0.4.6,

599 with modifications.

600

601 **Mendelian randomization**

602 We performed two-sample MR to test for a causal relationship between AF and relevant
603 diseases or traits. Although the statistical power to detect the associations with AF decreased, we
604 selected AF-associated variants from the trans-ancestry meta-analysis in combination with BBJ and
605 FIN to avoid sample overlap, and extracted summary statistics from a large database of genetic
606 associations in the UK biobank (<http://www.nealelab.is/uk-biobank/>). To identify independent
607 variants for exposure, genome-wide significant variants ($P < 5 \times 10^{-8}$) were pruned ($r^2 < 0.05$; LD
608 window of 10,000 kb; using European samples of 1KG for LD reference) as applied previously⁶³.
609 First, we assessed whether AF is causally associated with cardiovascular diseases using AF-
610 associated variants as instrument variables and variants associated with cardiovascular diseases as
611 outcome variables. Next, we assessed the causal effects of quantitative traits related to
612 anthropometry, metabolites, serum protein, kidney function, liver function, hematocyte count, and
613 blood pressure on AF, where variants associated with quantitative traits were used as instrument
614 variables and AF-associated variants as outcome variables. We used the inverse-variance-weighting
615 (IVW) method. To exclude horizontal pleiotropic outliers, we performed MR-PRESSO for
616 instrument variables⁶⁴. We also calculated Cochran's Q statistics for heterogeneity between the
617 causal effects of variants using IVW and the MR-Egger intercept for directional pleiotropy. All
618 analyses were performed using R v4.0.3, with R packages TwoSampleMR and MRPRESSO.

619 **Data availability**

620

621 Summary statistics of Japanese GWAS and polygenic risk scores derived in this study will be
622 publicly available at the National Bioscience Database Center (<https://humandbs.biosciencedbc.jp/>).

623

624 **Code Availability**

625 Code used in this study is available on reasonable request to the corresponding authors.

626

627 **Acknowledgements**

628

629 We thank the staff of BBJ for their assistance in collecting samples and clinical information. We also
630 thank A. P. Morris for providing us with MANTRA software and valuable advice.

631 This research was funded by the GRIFIN project of the Japan Agency for Medical Research and

632 Development (AMED) (nos. JP20km0405209 and JP20ek0109487 to K. Miyazawa, K. I., S. K., S.

633 N., H. Akazawa, and I. K.), MSD Life Science Foundation (to K. Miyazawa), the Japan Society for

634 the Promotion of Science (to K. Miyazawa, K. I. and H. I.), and Sakakibara Memorial Research

635 Grant from The Japan Research Promotion Society for Cardiovascular Diseases (to H. M.). BBJ was

636 supported by the Tailor-Made Medical Treatment Program of the Ministry of Education, Culture,

637 Sports, Science, and Technology (MEXT) and AMED under grant numbers JP17km0305002 and

638 JP17km0305001.

639

640 **Author Contributions**

641

642 K. Miyazawa, K. I., C. T., Y. K., H. Akazawa, and I. K. conceived and designed the study. C. T., K.

643 Matsuda, Y. M., M. K., and Y. K. collected and managed the BBJ sample. Y. M., A. T., M. K., and Y.

644 K. performed the genotyping. K. Miyazawa, K. I., Z. Z., H. M., C. T., S. O., and Y. K. performed the

645 statistical analyses. K. Miyazawa, K. I., Z. Z., H. M., H. I., M. A., K. O., Y. O., C. T., and S. O.

646 contributed to data processing, analysis, and interpretation. K. I., H. Aburatani, H. Akazawa, Y.K.
647 and I. K. supervised the study. K. Miyazawa, K. I., and M. H. wrote the manuscript, and many
648 authors have provided valuable edits.

649

650 **Competing interests**

651

652 The authors declare no competing interests associated with this manuscript.

653

654

655

656

657

658 **References**

- 659 1. Benjamin, E.J. *et al.* Heart Disease and Stroke Statistics-2019 Update: A Report From the
660 American Heart Association. *Circulation* **139**, e56-e528 (2019).
- 661 2. Staerk, L., Sherer, J.A., Ko, D., Benjamin, E.J. & Helm, R.H. Atrial Fibrillation:
662 Epidemiology, Pathophysiology, and Clinical Outcomes. *Circ. Res.* **120**, 1501-1517 (2017).
- 663 3. Healey, J.S. *et al.* Occurrence of death and stroke in patients in 47 countries 1 year after
664 presenting with atrial fibrillation: a cohort study. *Lancet* **388**, 1161-1169 (2016).
- 665 4. Kim, M.H., Johnston, S.S., Chu, B.C., Dalal, M.R. & Schulman, K.L. Estimation of total
666 incremental health care costs in patients with atrial fibrillation in the United States. *Circ.*
667 *Cardiovasc. Qual. Outcomes.* **4**, 313-320 (2011).
- 668 5. Christophersen, I.E. *et al.* Large-scale analyses of common and rare variants identify 12 new
669 loci associated with atrial fibrillation. *Nat. Genet.* **49**, 946-952 (2017).
- 670 6. Low, S.K. *et al.* Identification of six new genetic loci associated with atrial fibrillation in the
671 Japanese population. *Nat. Genet.* **49**, 953-958 (2017).
- 672 7. Nielsen, J.B. *et al.* Biobank-driven genomic discovery yields new insight into atrial
673 fibrillation biology. *Nat. Genet.* **50**, 1234-1239 (2018).
- 674 8. Roselli, C. *et al.* Multi-ethnic genome-wide association study for atrial fibrillation. *Nat. Genet.*
675 **50**, 1225-1233 (2018).
- 676 9. Karczewski, K.J. *et al.* The mutational constraint spectrum quantified from variation in
677 141,456 humans. *Nature* **581**, 434-443 (2020).
- 678 10. Jaganathan, K. *et al.* Predicting Splicing from Primary Sequence with Deep Learning. *Cell*
679 **176**, 535-548.e24 (2019).
- 680 11. Bonne, G. *et al.* Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-
681 Dreifuss muscular dystrophy. *Nat. Genet.* **21**, 285-288 (1999).
- 682 12. Capell, B.C. & Collins, F.S. Human laminopathies: nuclei gone genetically awry. *Nat. Rev.*
683 *Genet.* **7**, 940-952 (2006).
- 684 13. Zhou, C. *et al.* Novel nesprin-1 mutations associated with dilated cardiomyopathy cause

- 685 nuclear envelope disruption and defects in myogenesis. *Hum. Mol. Genet.* **26**, 2258-2276
686 (2017).
- 687 14. Wang, C. *et al.* Fibroblast growth factor homologous factor 13 regulates Na⁺ channels and
688 conduction velocity in murine hearts. *Circ. Res.* **109**, 775-782 (2011).
- 689 15. Lip, G.Y. *et al.* Sex-related differences in presentation, treatment, and outcome of patients
690 with atrial fibrillation in Europe: a report from the Euro Observational Research Programme
691 Pilot survey on Atrial Fibrillation. *Europace* **17**, 24-31 (2015).
- 692 16. Schnabel, R.B. *et al.* Gender differences in clinical presentation and 1-year outcomes in atrial
693 fibrillation. *Heart* **103**, 1024-1030 (2017).
- 694 17. Ball, J., Carrington, M.J., Wood, K.A., Stewart, S. & SAFETY Investigators. Women versus
695 men with chronic atrial fibrillation: insights from the Standard versus Atrial Fibrillation
696 spEcific management studY (SAFETY). *PLoS One* **8**, e65795 (2013).
- 697 18. Benjamin, E.J. *et al.* Impact of atrial fibrillation on the risk of death: the Framingham Heart
698 Study. *Circulation* **98**, 946-952 (1998).
- 699 19. Scheuermeyer, F.X. *et al.* There Are Sex Differences in the Demographics and Risk Profiles
700 of Emergency Department (ED) Patients With Atrial Fibrillation and Flutter, but no Apparent
701 Differences in ED Management or Outcomes. *Acad. Emerg. Med.* **22**, 1067-1075 (2015).
- 702 20. Conforto, T.L., Zhang, Y., Sherman, J. & Waxman, D.J. Impact of CUX2 on the female mouse
703 liver transcriptome: activation of female-biased genes and repression of male-biased genes.
704 *Mol. Cell. Biol.* **32**, 4611-4627 (2012).
- 705 21. Ling, G., Sugathan, A., Mazor, T., Fraenkel, E. & Waxman, D.J. Unbiased, genome-wide in
706 vivo mapping of transcriptional regulatory elements reveals sex differences in chromatin
707 structure associated with sex-specific liver gene expression. *Mol. Cell. Biol.* **30**, 5531-5544
708 (2010).
- 709 22. Lin, H. *et al.* Methylome-wide Association Study of Atrial Fibrillation in Framingham Heart
710 Study. *Sci. Rep.* **7**, 40377 (2017).
- 711 23. Battle, A. *et al.* Genetic effects on gene expression across human tissues. *Nature* **550**, 204-

- 712 213 (2017).
- 713 24. Rattka, M., Westphal, S., Gahr, B.M., Just, S. & Rottbauer, W. Spen deficiency interferes with
714 Connexin 43 expression and leads to heart failure in zebrafish. *J. Mol. Cell. Cardiol.* **155**, 25-
715 35 (2021).
- 716 25. Michela, P., Velia, V., Aldo, P. & Ada, P. Role of connexin 43 in cardiovascular diseases. *Eur.*
717 *J. Pharmacol.* **768**, 71-76 (2015).
- 718 26. den Hoed, M. *et al.* Identification of heart rate-associated loci and their effects on cardiac
719 conduction and rhythm disorders. *Nat. Genet.* **45**, 621-631 (2013).
- 720 27. Nolte, I.M. *et al.* Genetic loci associated with heart rate variability and their effects on cardiac
721 disease risk. *Nat. Commun.* **8**, 15805 (2017).
- 722 28. Chen, P.S., Chen, L.S., Fishbein, M.C., Lin, S.F. & Nattel, S. Role of the autonomic nervous
723 system in atrial fibrillation: pathophysiology and therapy. *Circ. Res.* **114**, 1500-1515 (2014).
- 724 29. Gudbjartsson, D.F. *et al.* A sequence variant in ZFH3 on 16q22 associates with atrial
725 fibrillation and ischemic stroke. *Nat. Genet.* **41**, 876-878 (2009).
- 726 30. Zaw, K.T.T. *et al.* Association of ZFH3 gene variation with atrial fibrillation, cerebral
727 infarction, and lung thromboembolism: An autopsy study. *J. Cardiol.* **70**, 180-184 (2017).
- 728 31. Amendt, B.A., Sutherland, L.B., Semina, E.V. & Russo, A.F. The molecular basis of Rieger
729 syndrome. Analysis of Pitx2 homeodomain protein activities. *J. Biol. Chem.* **273**, 20066-
730 20072 (1998).
- 731 32. Oki, S. *et al.* ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq
732 data. *EMBO Rep.* **19**, e46255 (2018).
- 733 33. Ramji, D.P. & Foka, P. CCAAT/enhancer-binding proteins: structure, function and regulation.
734 *Biochem. J* **365**, 561-575 (2002).
- 735 34. Akiyama, M. *et al.* Genome-wide association study identifies 112 new loci for body mass
736 index in the Japanese population. *Nat. Genet.* **49**, 1458-1467 (2017).
- 737 35. Kanai, M. *et al.* Genetic analysis of quantitative traits in the Japanese population links cell
738 types to complex human diseases. *Nat. Genet.* **50**, 390-400 (2018).

- 739 36. Akiyama, M. *et al.* Characterizing rare and low-frequency height-associated variants in the
740 Japanese population. *Nat. Commun.* **10**, 4393 (2019).
- 741 37. Bustin, M. & Reeves, R. High-mobility-group chromosomal proteins: architectural
742 components that facilitate chromatin function. *Prog. Nucleic Acid Res. Mol. Biol.* **54**, 35-100
743 (1996).
- 744 38. Chiefari, E. *et al.* A polymorphism of HMGA1 is associated with increased risk of metabolic
745 syndrome and related components. *Sci. Rep.* **3**, 1491 (2013).
- 746 39. Pers, T.H. *et al.* Biological interpretation of genome-wide association studies using predicted
747 gene functions. *Nat. Commun.* **6**, 5890 (2015).
- 748 40. Sharma, M. *et al.* hZimp10 is an androgen receptor co-activator and forms a complex with
749 SUMO-1 at replication foci. *EMBO J.* **22**, 6101-6114 (2003).
- 750 41. Rodriguez-Magadán, H., Merino, E., Schnabel, D., Ramírez, L. & Lomelí, H. Spatial and
751 temporal expression of Zimp7 and Zimp10 PIAS-like proteins in the developing mouse
752 embryo. *Gene Expr. Patterns* **8**, 206-213 (2008).
- 753 42. Henderson, P., van Limbergen, J.E., Wilson, D.C., Satsangi, J. & Russell, R.K. Genetics of
754 childhood-onset inflammatory bowel disease. *Inflamm. Bowel Dis.* **17**, 346-361 (2011).
- 755 43. Beliakoff, J. *et al.* The PIAS-like protein Zimp10 is essential for embryonic viability and
756 proper vascular development. *Mol. Cell. Biol.* **28**, 282-292 (2008).
- 757 44. Hu, Y.F., Chen, Y.J., Lin, Y.J. & Chen, S.A. Inflammation and the pathogenesis of atrial
758 fibrillation. *Nat. Rev. Cardiol.* **12**, 230-243 (2015).
- 759 45. Schnabel, R.B. *et al.* Large-scale candidate gene analysis in whites and African Americans
760 identifies IL6R polymorphism in relation to atrial fibrillation: the National Heart, Lung, and
761 Blood Institute's Candidate Gene Association Resource (CARE) project. *Circ. Cardiovasc.*
762 *Genet.* **4**, 557-564 (2011).
- 763 46. Nagai, N. *et al.* Downregulation of ERG and FLI1 expression in endothelial cells triggers
764 endothelial-to-mesenchymal transition. *PLoS Genet.* **14**, e1007826 (2018).
- 765 47. Kalna, V. *et al.* The Transcription Factor ERG Regulates Super-Enhancers Associated With

- 766 an Endothelial-Specific Gene Expression Program. *Circ. Res.* **124**, 1337-1349 (2019).
- 767 48. Levin, M.G. *et al.* Genetics of height and risk of atrial fibrillation: A Mendelian randomization
768 study. *PLoS Med.* **17**, e1003288 (2020).
- 769 49. Shah, A.V., Birdsey, G.M. & Randi, A.M. Regulation of endothelial homeostasis, vascular
770 development and angiogenesis by the transcription factor ERG. *Vascul. Pharmacol.* **86**, 3-13
771 (2016).
- 772 50. Guazzi, M. & Arena, R. Endothelial dysfunction and pathophysiological correlates in atrial
773 fibrillation. *Heart* **95**, 102-106 (2009).
- 774 51. Khan, A.A., Thomas, G.N., Lip, G.Y.H. & Shantsila, A. Endothelial function in patients with
775 atrial fibrillation. *Ann. Med.* **52**, 1-11 (2020).
- 776 52. Vijayaraj, P. *et al.* Erg is a crucial regulator of endocardial-mesenchymal transformation
777 during cardiac valve morphogenesis. *Development* **139**, 3973-3985 (2012).
- 778 53. Birdsey, G.M. *et al.* The endothelial transcription factor ERG promotes vascular stability and
779 growth through Wnt/ β -catenin signaling. *Dev. Cell* **32**, 82-96 (2015).
- 780 54. Abecasis, G.R. *et al.* A map of human genome variation from population-scale sequencing.
781 *Nature* **467**, 1061-1073 (2010).
- 782 55. Morris, A.P. Transethnic meta-analysis of genomewide association studies. *Genet. Epidemiol.*
783 **35**, 809-822 (2011).
- 784 56. Frey, B.J. & Dueck, D. Clustering by passing messages between data points. *Science* **315**,
785 972-976 (2007).
- 786 57. Marouli, E. *et al.* Rare and low-frequency coding variants alter human adult height. *Nature*
787 **542**, 186-190 (2017).
- 788 58. Malik, R. *et al.* Multiancestry genome-wide association study of 520,000 subjects identifies
789 32 loci associated with stroke and stroke subtypes. *Nat. Genet.* **50**, 524-537 (2018).
- 790 59. Barbeira, A.N. *et al.* Exploring the phenotypic consequences of tissue specific gene
791 expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825 (2018).
- 792 60. Robinson, J.T. *et al.* Integrative genomics viewer. *Nat. Biotechnol.* **29**, 24-26 (2011).

- 793 61. Nagai, A. *et al.* Overview of the BioBank Japan Project: Study design and profile. *J.*
794 *Epidemiol.* **27**, S2-S8 (2017).
- 795 62. Hirata, M. *et al.* Cross-sectional analysis of BioBank Japan clinical data: A large cohort of
796 200,000 patients with 47 common diseases. *J. Epidemiol.* **27**, S9-S21 (2017).
- 797 63. Shah, S. *et al.* Genome-wide association and Mendelian randomisation analysis provide
798 insights into the pathogenesis of heart failure. *Nat. Commun.* **11**, 163 (2020).
- 799 64. Verbanck, M., Chen, C.Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy
800 in causal relationships inferred from Mendelian randomization between complex traits and
801 diseases. *Nat. Genet.* **50**, 693-698 (2018).
- 802
- 803

804
805
806

Table 1 | Novel association loci in the Japanese genome-wide association study (GWAS). Sentinel variants in novel loci with a genome-wide significance in the Japanese GWAS (9,826 cases and 140,446 controls). CHR, chromosome; rsID, reference SNP cluster ID; POS, position (hg19); REF, reference allele; ALT, alternate allele; BBJ, BioBank Japan; AAF, alternate allele frequency; EUR, European populations; SE, standard error.

CHR	POS (hg19)	rsID	REF	ALT	AAF			Beta	SE	P	Gene	Annotation
					BBJ	gnomAD EUR (non-Finnish)	gnomAD EUR (Finnish)					
6	152466619	rs202030113	T	C	0.012	0	0	0.352	0.063	1.90E-08	<i>SYNE1</i>	Intronic
12	104471663	rs2930856	C	T	0.579	0.861	0.854	0.090	0.015	5.80E-09	<i>HCFC2</i>	Intronic
16	30619745	rs1055894680	C	T	0.001	<0.001	0.001	1.215	0.158	1.58E-14	<i>ZNF689</i>	Intronic
X	23399501	rs73205368	T	C	0.284	0.045	0.015	0.089	0.012	7.50E-13	<i>PTCHD1</i>	Intronic
X	137790580	rs778479352	T	C	0.002	0	0	0.692	0.075	1.62E-20	<i>FGF13</i>	Intronic


807

808 **Table 2 | Novel association loci in the trans-ancestry meta-analysis.** Sentinel variants in novel loci with a genome-wide significance in the Japanese GWAS
 809 (77,690 cases and 1,167,040 controls). CHR, chromosome; POS, position (hg19); REF, reference allele; ALT, alternate allele; rsID, reference SNP cluster ID;
 810 BF, Bayes factor; AAF, alternate allele frequency; BBJ, BioBank Japan; SE, standard error; ncRNA, non-coding RNA.

CHR	POS (hg19)	REF	ALT	rsID	Gene	Annotation	log10BF	BBJ				EUR				FIN			
								AAF	Beta	SE	P	AAF	Beta	SE	P	AAF	Beta	SE	P
1	918617	G	A	rs4970418	<i>PERM1, HES4</i>	intergenic	7.647	0.076	0.062	0.028	2.9E-02	0.167	0.044	0.010	7.5E-06	0.175	0.102	0.025	4.1E-05
1	16199051	T	C	rs9782984	<i>MIR5096</i>	ncRNA intronic	13.984	0.681	0.057	0.016	4.0E-04	0.353	0.041	0.007	3.2E-09	0.412	0.102	0.019	1.2E-07
1	39385714	G	A	rs75414548	<i>RHBDL2</i>	intronic	6.970	0.723	-0.075	0.017	1.5E-05	0.883	-0.055	0.014	8.4E-05	0.835	-0.035	0.025	1.7E-01
1	100149308	G	A	rs1933723	<i>PALMD</i>	intronic	13.485	0.676	0.057	0.016	3.9E-04	0.847	0.062	0.010	2.0E-10	0.788	0.078	0.023	7.2E-04
4	71776935	A	C	rs12512502	<i>MOB1B</i>	intronic	6.439	0.060	0.068	0.032	3.5E-02	0.077	0.068	0.015	4.4E-06	0.059	0.106	0.040	8.2E-03
4	83910712	T	G	rs6841049	<i>LIN54</i>	intronic	8.571	0.686	-0.005	0.016	7.5E-01	0.648	-0.044	0.007	2.9E-10	0.662	-0.056	0.020	5.1E-03
5	139703286	T	C	rs17118812	<i>PFDF1, HBEGF</i>	intergenic	10.411	0.095	-0.008	0.025	7.5E-01	0.033	0.145	0.020	1.7E-13	0.040	0.019	0.047	6.9E-01
6	22598259	C	T	rs7766436	<i>HDGFL1, LOC105374972</i>	intergenic	6.298	0.698	0.034	0.016	3.8E-02	0.677	0.036	0.007	5.2E-07	0.664	0.027	0.020	1.8E-01
6	76164589	C	A	rs12209223	<i>LOC101928540</i>	ncRNA exonic	18.445	0.502	0.087	0.015	6.1E-09	0.097	0.066	0.011	2.2E-09	0.185	0.110	0.024	5.2E-06
6	135119089	C	T	rs4896104	<i>LOC101928304, ALDH8A1</i>	intergenic	13.267	0.289	0.055	0.016	7.5E-04	0.564	0.049	0.007	5.0E-13	0.567	0.021	0.019	2.8E-01
7	105612736	A	G	rs2727757	<i>CDHR3</i>	intronic	8.256	0.489	0.084	0.015	1.6E-08	0.195	0.034	0.008	4.5E-05	0.186	0.017	0.024	4.8E-01
8	118863412	A	T	rs17430357	<i>EXT1</i>	intronic	87.114	0.085	0.071	0.026	6.2E-03	0.333	0.135	0.007	3.1E-79	0.361	0.125	0.020	1.6E-10
9	119181794	G	A	rs17303101	<i>PAPPA, ASTN2</i>	intergenic	62.406	0.461	-0.150	0.015	2.0E-23	0.535	-0.091	0.007	3.3E-42	0.523	-0.072	0.019	1.2E-04
10	32772734	C	T	rs11527634	<i>CCDC7</i>	intronic	39.187	0.305	-0.157	0.017	3.8E-21	0.552	-0.060	0.007	1.6E-19	0.643	-0.078	0.020	8.0E-05
10	50485434	G	A	rs76460895	<i>C10orf128, C10orf71-AS1</i>	intergenic	7.418	0.363	0.020	0.015	2.0E-01	0.416	0.038	0.007	2.1E-08	0.364	0.041	0.020	3.6E-02
10	80898969	G	T	rs1769758	<i>ZMIZ1</i>	intronic	14.173	0.124	0.102	0.022	3.7E-06	0.800	0.060	0.009	3.2E-12	0.713	0.030	0.021	1.5E-01
11	3890059	C	T	rs7126870	<i>STIM1</i>	intronic	6.407	0.674	0.018	0.016	2.6E-01	0.613	0.038	0.007	3.2E-08	0.620	0.022	0.019	2.7E-01
11	14036189	G	A	rs10500790	<i>SPON1</i>	intronic	31.262	0.325	-0.089	0.016	3.1E-08	0.385	-0.066	0.007	2.9E-22	0.340	-0.100	0.020	4.8E-07
11	95089882	C	T	rs517938	<i>LOC100129203, FAM76B</i>	intergenic	15.745	0.682	-0.038	0.016	1.8E-02	0.464	-0.055	0.007	1.1E-16	0.530	-0.031	0.019	1.0E-01
12	12886027	G	A	rs10845620	<i>APOLD1</i>	intronic	8.311	0.194	-0.003	0.019	8.6E-01	0.179	-0.053	0.009	9.5E-10	0.149	-0.083	0.027	1.8E-03
12	104492003	A	G	rs2629755	<i>HCFC2</i>	intronic	6.641	0.664	0.031	0.016	5.3E-02	0.100	0.059	0.011	4.9E-08	0.085	0.035	0.033	2.9E-01
12	110082115	T	C	rs1344543	<i>MVK, FAM222A</i>	intergenic	6.893	0.504	0.039	0.015	9.3E-03	0.357	0.031	0.007	5.0E-06	0.363	0.052	0.020	8.4E-03
12	113196733	G	A	rs11614295	<i>RPH3A</i>	intronic	17.213	0.390	0.046	0.016	3.3E-03	0.485	0.055	0.007	2.0E-16	0.484	0.045	0.019	1.7E-02
13	22111521	C	A	rs11841562	<i>MICU2</i>	intronic	27.396	0.435	0.052	0.015	5.1E-04	0.140	0.094	0.009	8.3E-24	0.153	0.119	0.026	4.4E-06
13	74520186	T	A	rs1886512	<i>KLF12</i>	intronic	28.423	0.690	0.093	0.016	1.4E-08	0.392	0.068	0.007	5.7E-24	0.454	0.039	0.019	3.7E-02
16	15902715	G	A	rs9284324	<i>MYH11</i>	intronic	9.014	0.132	-0.043	0.022	5.6E-02	0.344	-0.044	0.007	5.0E-10	0.372	-0.030	0.019	1.2E-01
18	77156537	C	G	rs8096658	<i>NFATC1</i>	intronic	32.733	0.299	0.085	0.016	1.4E-07	0.640	0.071	0.007	1.8E-24	0.610	0.094	0.019	1.3E-06
19	48142746	A	C	rs11881441	<i>BICRA</i>	intronic	13.406	0.308	-0.064	0.016	9.7E-05	0.295	-0.044	0.007	2.2E-09	0.246	-0.090	0.022	4.6E-05
20	36841914	G	A	rs3746471	<i>KIAA1755</i>	exonic	22.109	0.784	0.066	0.018	3.2E-04	0.602	0.062	0.007	6.9E-20	0.546	0.052	0.019	6.3E-03
22	21999229	C	G	rs5754508	<i>SDF2L1</i>	downstream	12.534	0.215	-0.062	0.019	9.1E-04	0.379	-0.045	0.007	1.3E-10	0.323	-0.057	0.020	4.5E-03
22	42189407	T	G	rs139557	<i>MEI1</i>	intronic	8.711	0.718	0.025	0.017	1.4E-01	0.364	0.041	0.007	2.7E-09	0.336	0.044	0.020	2.6E-02
X	23399501	T	C	rs73205368	<i>PTCHD1</i>	intronic	12.261	0.149	-0.024	0.021	2.6E-01	0.404	-0.046	0.007	2.4E-11	0.487	-0.075	0.019	6.6E-05
X	137418967	C	A	rs1891095	<i>ZIC3, LINC00889</i>	intergenic	17.173	0.514	0.053	0.015	3.9E-04	0.651	0.056	0.007	1.6E-15	0.605	0.049	0.019	1.1E-02

811

812



813

814 **Fig. 1 | Manhattan plot for the trans-ancestry meta-analysis.** The results of the trans-ancestry meta-


815 analysis (77,690 AF cases and 1,167,040 controls) are shown. The $\text{log}_{10} \text{BF}$ s on the y axis are shown

816 against the genomic positions (hg19) on the x axis. Association signals that reached a genome-wide

817 significance level ($\text{log}_{10} \text{BF} > 6$) are shown in blue if previously reported loci and in red if novel loci.

818 AF, atrial fibrillation; BF, Bayes factor.


819



820

821 **Fig. 2 | Transcriptome-wide association analysis.** **a**, Volcano plot showing individual genes with the
 822 effect size and the $-\log_{10} P$ value for TWAS based on atrial appendage and left ventricular tissues from
 823 GTEx project. Significant genes adjusted Bonferroni correction for all tested genes in each tissue (P
 824 value $< 0.05/5,988$ for atrial appendage and $< 0.05/5,378$ for left ventricle) are highlighted with red
 825 (positive effect of predicted gene expression on AF) and blue (negative effect of predicted gene
 826 expression on AF). **b**, Number of genes located close to the lead variants (red), identified by TWAS,
 827 (blue) and overlapped between them (green) in atrial appendage and left ventricular tissues. **c**,

828 Distribution of genes identified by TWAS based on physical distance to the lead variants in atrial
829 appendage and left ventricular tissues. **d**, Canonical pathways enriched in gene sets identified by
830 transcriptome-wide association study in atrial appendage (yellow) and left ventricular tissues (blue).
831 TWAS, transcriptome-wide association study; GTEx, Genotype-Tissue Expression; AF, atrial
832 fibrillation.



833

834 **Fig. 3 | Enrichment analysis of transcription factor for AF-associated loci. a**, Volcano plot analysis.

835 Each point represents ChIP-seq experiment and is highlighted as red for cardiovascular cells, green

836 for induced pluripotent stem cell-derived cardiac cells, blue for muscle cells, and grey for other cell

837 types. The x axis shows \log_2 -transformed hold enrichment of transcription factor in 150 AF-associated


838 loci, compared to randomly selected 150 genome regions. The y axis shows \log_{10} -transformed P value

839 for enrichment. The dashed line indicated significance threshold level of $P = 0.05$, and the dotted line

840 indicates $P = 0.05/15,109$. **b**, *SCN10A* locus showing AF-associated variants with $r^2 > 0.8$ in European

841 samples of 1KG and ChIP-seq track of ERG experiment ($P = 1.0 \times 10^{-8}$) and H3K27ac in iPSC-

842 derived cardiac cells. AF, atrial fibrillation; iPSC, induced pluripotent stem cell.



843

844 **Fig. 4 | Performance of polygenic risk score (PRS) derived from the transethnic meta-analysis.**

845 Each point indicates the median Nagelkerke's pseudo R^2 for PRS in the Japanese test cohort (2,953


846 cases and 21,194 controls). Error bars represent the 95% CI. Median pseudo R^2 and CI were estimated

847 from 5×10^4 times bootstrapping. The color of each point indicates the ancestry that was included in

848 the discovery population. The size of each point indicates the number of cases in the discovery


849 population. CI, confidence interval.

850



851


852 **Fig. 5 | Impact of AF-PRS on long-term cardiovascular mortality.** **A, b**, Association analysis
 853 between AF-PRS and age of AF onset. **A**, Each point represents median age of onset according to the
 854 PRS quintile. **B**, Each point and error bar represent estimated β and 95% CI obtained from the linear
 855 regression model. **C**, Association between AF-PRS and stroke subtypes in individuals without AF.
 856 Data are presented as estimated ORs and 95% CI for 1 s.d. increase in AF-PRS. **c, d**, Kaplan-Meier
 857 estimates of cumulative events from cardiovascular mortality (**a**) and stroke death (**b**) with 95% CI.
 858 Individuals are classified into high PRS (top 10 percentile, red), low PRS (bottom 10 percentile, blue),
 859 and intermediate (others, green). **e**, Effects of AF-PRS on long-term mortality. Data are presented as
 860 estimated HRs and 95% CIs for a 1 s.d. increase in AF-PRS. AF, atrial fibrillation; PRS, polygenic
 861 risk score; CI, confidence interval; OR, odds ratio; HR, hazard ratio; s.d., standard deviation; CV,
 862 cardiovascular death; HF, congestive heart failure death; IHD, ischemic heart disease death.



863

864 **Fig. 6 | Causal effect of AF on cardiovascular and cerebrovascular diseases.** Each point and error
 865 bar represent the causal estimates on the OR scale and the 95% CI for these ORs respectively. We
 866 analyzed MR analysis for the estimation of the causal effects using variants after excluding horizontal
 867 pleiotropic outliers. *P* values were determined from the IVW two-sample MR method. AF, atrial
 868 fibrillation; OR, odds ratio; CI, confidence interval; MR, sample Mendelian randomization; IVW,
 869 inverse-variance weighting; AV block, atrioventricular block; HF, heart failure; TIA, transient
 870 ischemic attack; IHD, ischemic heart disease; PAD, peripheral artery disease; SAH, subarachnoid
 871 hemorrhage.

872



1

2 **Supplementary Fig. 1 | Overview of the study design.** Top, overview of the Japanese cohort of 9,826


3 AF cases and 140,446 controls with reference panel. Middle, GWAS summary of each study and the

4 trans-ancestry meta-analysis with the number of cases and controls. Bottom, overview of the

5 downstream analyses for AF-associated variants in the trans-ancestry meta-analysis. GWAS, genome-

6 wide association study; JENGER, Japanese ENcyclopedia GENetic associations by Riken; MR,

7 Mendelian randomization; PRS, polygenic risk score; TWAS, transcriptome-wide association study.



8

9 **Supplementary Fig. 2 | Manhattan plot for the Japanese GWAS.** The results of the Japanese GWAS


10 (9,826 AF cases and 140,446 controls) are shown. The negative $\log_{10} P$ values on the *y-axis* are shown

11 against the genomic positions (hg19) on the *x-axis*. Association signals that reached a genome-wide

12 significance level ($P < 5.0 \times 10^{-8}$) are shown in blue if previously reported loci and in red if novel loci.


13 GWAS, genome-wide association study; AF, atrial fibrillation.

14



15
16 **Supplementary Fig. 3 | Independent association signals in AF development.** The ORs for AF
17 development of AF 49 independent signals in the Japanese GWAS (31 lead variants and 18
18 independent variants) were plotted against the risk allele frequencies. Novel variants are highlighted
19 in orange with annotated genes. AF, atrial fibrillation; OR, odds ratio; GWAS, genome-wide
20 association study.


21



22

23 **Supplementary Fig. 4 | Sex-stratified GWAS.** **a**, Miami plot for sex-stratified GWAS. Upper panel
 24 for male GWAS (N = 81,050: 6,825 cases and 74,225 controls) and lower panel for female GWAS (N
 25 = 69,222: 3,001 cases and 66,221 controls). Association signals that reached a genome-wide

26 significance level ($P < 5.0 \times 10^{-8}$) are shown in blue if previously reported loci and in red if novel loci.
27 **b**, Comparison of estimated effect sizes of the lead variants identified in both male and female GWAS.
28 Data are presented as estimated β and 95% confidence. The lead variants with significant heterogeneity
29 ($P_{het} < 0.0001$) are highlighted in orange, and ρ indicates Spearman's correlation coefficient. GWAS,
30 genome-wide association study.




31

32

33 **Supplementary Fig. 5 | CUX2 gene expression in liver.** Violin plots showing the distribution of

34 CUX2 gene expression in the liver based on GTEx data.



35

36 **Supplementary Fig. 6 | Comparison of allele frequencies and allelic effects among ancestries**

37 **and fine mapping derived from credible set analyses a-c**, Comparisons of alternate allele

38 frequencies of the 150 lead variants identified in the trans-ancestry meta-analysis (a, BBJ versus

39 EUR; b, BBJ versus FIN; c, EUR versus FIN). d-f, Comparison of estimated effect sizes of 150 lead

40 variants. Data are presented as estimated β and 95% CI in each study (d, BBJ versus EUR; e, BBJ


41 versus FIN; f, EUR versus FIN). Grey points indicate previously reported loci, and orange points

42 indicate newly identified loci in this study. ρ indicates Spearman's correlation coefficient. g, h,

43 Comparisons of the number of variants included in the 99% credible sets derived from each


44 combination of the meta-analysis (g, EUR + BBJ versus EUR + FIN; h, BBJ + EUR + FIN versus

45 BBJ + EUR). Both *the x* and *y* axes represent the log-transformed number of variants in the 99%
46 credible sets. BBJ, BioBank Japan; EUR, European population; FIN, FinnGen data release 2; CI,
47 confidence interval.



48

49 **Supplementary Fig. 7 | rs67329386 and transcription factor. *ZFH3* locus showing rs67329386**
50 (highlighted in yellow) and proxies with $r^2 > 0.8$ in European samples in 1KG along with ChIP-seq
51 track of CEBPB experiments in mesenchymal stem cells.



52

53 **Supplementary Fig. 8 | Overlap between AF-associated signals and variants associated with**

54 **quantitative traits** Heat-map representation of the AF-associated loci, in which AF-associated

55 variants in LD with $r^2 > 0.6$ in East Asian samples of 1KG overlapped with variants associated with


56 at least one of the quantitative traits. The Z score of QTL alleles that were in accordance with the AF

57 risk allele are shown. Positive values are shown in red, and negative values are shown in blue. The

58 rows show quantitative traits, and the column shows the chromosome and base position of AF-

59 associated signals. AF, atrial fibrillation; LD, linkage disequilibrium; QTL, quantitative trait loci.

60




61

62 **Supplementary Fig. 9 Tissue enrichment and eQTL analysis** The results of tissue enrichment

63 analysis ($\log_{10} BF > 5$ and 16,181 variants). The *x-axis* indicates the $-\log_{10} P$ value. Forty-eight

64 exemplar tissues (Methods) were tested, and the significance level was set at $P = 1 \times 10^{-3}$ (0.05/48).

65 eQTL, expression quantitative trait locus; BF, Bayes factor.




66

67 **Supplementary Fig. 10 | Ion channel-related gene and ERG. a, *CAMK2D* locus b, *CAV1* locus, c,**

68 *KCNH2* locus d, *HCN4* locus showing AF-associated variants ($r^2 > 0.8$ in European samples in

69 1KG) and ChIP-seq track of ERG experiment ($P = 1.0 \times 10^{-8}$) and histone modification markers in

70 iPSC-derived cardiac cells. iPSC, induced pluripotent stem cells.



71


72 **Supplementary Fig. 11 | PRS distribution and AF prevalence. a**, Distribution of PRS in the case

73 and control samples for each combination of GWAS. **b** Prevalence of AF based on the AF-PRS deciles

74 in each combination of GWAS. Data are presented as medians and 95% CI. PRS, polygenic risk score;


75 AF, atrial fibrillation; GWAS, genome-wide association study; CI, confidence interval.

76



77

78 **Supplementary Fig. 12 | Impact of AF-PRS on the age of AF onset and long-term mortality a,**
79 **Comparison of the age of AF onset between samples with high PRS and those with remaining PRS. b,**
80 **Kaplan-Meier estimates of cumulative events from all-cause death, heart failure death, and ischemic**
81 **heart disease death with 95% CI. Individuals are classified into high PRS (top 10 percentile, red), low**
82 **PRS (bottom 10 percentile, blue), and intermediate (others, green). AF, atrial fibrillation; PRS,**
83 **polygenic risk score; CI, confidence interval.**



84

85 **Supplementary Fig. 13 | Causal effect of quantitative traits on AF development** Each point and

86 error bar represents the causal estimates on the OR scale and the 95% CI for these ORs, respectively.

87 We analyzed the MR analysis to estimate the causal effects using variants after excluding horizontal

88 pleiotropic outliers. The *P* values were determined using the IVW two-sample MR method. OR, odds

89 ratio; MR, Mendelian randomization; IVW, inverse-variance-weighting; DBP, diastolic blood

90 pressure; SBP, systolic blood pressure; PP, pulse pressure; BMI, body mass index; Neu, neutrophil

91 count; MCH, mean corpuscular hemoglobin; WBC, white blood cell count; PLT, platelet count; TP,

92 total protein; MCHC, mean corpuscular hemoglobin concentration; eGFR, estimated glomerular

93 filtration rate; MCV, mean corpuscular volume; UA uric acid; Eos, eosinophil count; ALP, alkaline


94 phosphatase; Baso, basophil count; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; HDL,

95 high-density lipoprotein cholesterol; Mono, monocyte count; BUN, blood urea nitrogen; TG,

96 triglyceride; Cre, serum creatinine; RBC, red blood cell; Hb, hemoglobin; AST, aspartate

97 aminotransferase; LDL, low-density lipoprotein cholesterol; Lym, lymphocyte count; Alb, albumin;

98 HCT, hematocrit; ALT, alanine aminotransferase; Glu, blood sugar



99

100 **Supplementary Fig. 14 | Quantile-quantile plot for GWAS of three studies. a**, the Japanese GWAS.

101 **b**, GWAS of a meta-analysis in European population (EUR). **c**, GWAS in data from FinnGen project






102 (FIN). GWAS, genome-wide association study.

103









Supplementary Dataset









1. Novel 5 loci in the Japanese GWAS
2. Previously reported 26 loci in the Japanese GWAS
3. Novel 33 loci in the trans-ancestry meta-GWAS
4. Previously reported 127 loci in the trans-ancestry meta-GWAS









1. Novel 5 loci in the Japanese GWAS





2. Previously reported 26 loci in the Japanese GWAS










































3. Novel 33 loci in the trans-ancestry meta-GWAS











4. Previously reported 127 loci in the trans-ancestry meta-GWAS

